Edesa Biotech (EDSA) Fundamental Analysis: Revenue, Earnings & Valuation

5.19 / 10

Netural

Fundamental analysis rates EDSA at 5.2/10, indicating a balanced profile. Strengths include high cash‑to‑market, strong inventory turnover, robust fixed‑asset utilization and rapid revenue growth. Weaknesses are low PB‑ROE, modest revenue‑to‑market, and thin gross margin, suggesting mixed quality.

Analysis Checks(6/10)

Revenue-MV

Value-0.11

Score1/3

Weight11.82%

1M Return4.95%

Total operating revenue (YoY growth rate %)

Value134.00

Score3/3

Weight3.06%

1M Return1.54%

Inventory turnover ratio

Value103.94

Score3/3

Weight15.68%

1M Return6.74%

Gross profit margin (%)

Value41.83

Score1/3

Weight-1.11%

1M Return-0.63%

PB-ROE

Value-0.39

Score1/3

Weight13.14%

1M Return5.29%

Income tax / Total profit (%)

Value-0.01

Score1/3

Weight-0.90%

1M Return-0.50%

Fixed assets turnover ratio

Value9306.28

Score3/3

Weight2.02%

1M Return1.06%

Cost of sales ratio (%)

Value64.41

Score3/3

Weight9.07%

1M Return4.32%

Asset-MV

Value-0.55

Score3/3

Weight33.29%

1M Return11.84%

Cash-MV

Value0.02

Score2/3

Weight13.93%

1M Return5.94%

Is EDSA undervalued or overvalued?

EDSA scores 5.19/10 on fundamentals and holds a Fair valuation at present. Backed by its -17.02% ROE, 0.00% net margin, -5.93 P/E ratio, 3.32 P/B ratio, and 42.78% earnings growth, these metrics solidify its Netural investment rating.